Dosing and uses of Sandostatin (Antidote), Sandostatin LAR Depot (octreotide (Antidote))
Adult dosage forms and strengths
injectable
- 50mcg/mL
- 100mcg/mL
- 200mcg/mL
- 500mcg/mL
- 1000mcg/mL
Sulfonylurea Overdose
Used for sulfonylurea overdoses when more than 1-2 boluses of D50W are ineffective to control hypoglycemia (will be "glucose sparing")
50-100 mcg SC/IV BID/TID, adjust according to blood glucose
For IV, dilute in 50 mL 0.9% NaCl or D5W and infuse over 15-30 minutes (may be given IV push over 3 minutes)
Pediatric dosage forms and strengths
injectable
- 50mcg/mL
- 100mcg/mL
- 200mcg/mL
- 500mcg/mL
- 1000mcg/mL
Sulfonylurea Overdose
Used for sulfonylurea overdoses when more than 1-2 boluses of D50W are ineffective to control hypoglycemia (will be "glucose sparing")
Not well-established
1 mcg/kg SC q12hr OR 4-5 mcg/kg/day divided QID SC
Severe refractory cases, start continuous IV infusion at 15 ng/kg/min and titrate to response
Sandostatin (Antidote), Sandostatin LAR Depot (octreotide (Antidote)) adverse (side) effects
Frequency not defined
Conduction abnormalities
CHF
Dizziness
Fatigue
Headache
Diarrhea
Nausea
Pain at injection site
Pregnancy and lactation
Pregnancy category: B
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Sandostatin (Antidote), Sandostatin LAR Depot (octreotide (Antidote))
Mechanism of action
An analogue of somatostatin
Antagonizes pancreatic insulin release
